Advanced Filters
noise

San Diego, California Clinical Trials

A listing of San Diego, California clinical trials actively recruiting patient volunteers.

Found 287 clinical trials
M Michelle L Weber Rawlins, PhD,ATC

Creatine Supplementation in Concussion Recovery

The proposed study aims to compare concussion recovery in those supplementing creatine and those not supplementing creatine. Specific aim 1: To compare number of days until asymptomatic between those taking creatine vs. those not taking creatine following a concussion. Hypothesis: The investigators hypothesize that individuals taking creatine will become asymptomatic …

18 - 35 years of age All Phase N/A
R Razia Ludin

Sylfirm X Radiofrequency Microneedling for the Treatment of Melasma

Microneedling radiofrequency technology has been shown in clinical studies to improve skin quality, tone, pigment, and to treat various skin conditions related to aging. The purpose of this study is to evaluate efficacy and safety of Sylfrim X device for the treatment of melasma.

18 - 70 years of age Female Phase N/A
M Michael Kampp

Strategy for Improving Stroke Treatment Response

SISTER is a Phase-II, prospective, randomized, placebo-controlled, blinded, dose finding trial that aims to determine the safety and preliminary efficacy of TS23, a monoclonal antibody against the alpha-2 antiplasmin (a2-AP), in acute ischemic stroke.

18 years of age All Phase 2

A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Adult Participants at Increased Genetic Risk for This Condition

This study is researching an investigational drug, ALN-HSD called "study drug". This study is focused on participants who are known to have metabolic dysfunction-associated steatohepatitis (MASH). MASH is a form of metabolic dysfunction-associated steatotic liver disease (MASLD). MASH occurs when fat builds up in liver cells, damaging them, and making …

18 - 75 years of age All Phase 2
R Recruiting Contact

A Phase 1 Study to Evaluate Safety, Tolerability and Pharmacokinetics of TIX100 in Healthy Subjects

A Single Center, Single Dose, Randomized, Placebo-controlled Study to Evaluate Safety, Tolerability and Pharmacokinetics of Orally Administered TIX100 in Healthy Subjects

18 - 70 years of age All Phase 1
S Sara Gorczynski, DPT

Evaluating the Effectiveness of Clinical Practice Guideline Adherence for Patellofemoral Pain

The overall goal of this multisite, randomized clinical trial is to evaluate the short- and long-term effectiveness of a Clinical Practice Guideline (CPG)-adherent physical therapy approach to patellofemoral pain (PFP) management among military Service members. The main questions it aims to answer are: Can a CPG-adherent care approach to PFP …

18 years of age All Phase N/A
A ASCEND-IBD Trial Center

A First-in-Human Single and Multiple Ascending Dose Study of MT-201

First-in-human study to evaluate the safety, tolerability, pharmacokinetics (PK), and immunogenicity of single and multiple doses of MT-201 in healthy participants.

19 - 55 years of age All Phase 1
R Rita Mehta, MD

Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial

This phase II trial evaluates whether genetic testing in prostate cancer is helpful in deciding which study treatment patients are assigned. Patient cancer tissue samples are obtained from a previous surgery or biopsy procedure and tested for deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) abnormalities or mutations in their cancer. …

18 years of age All Phase 2
A ASCEND-IBD Trial Center

A First-in-Human Single and Multiple Ascending Dose Study of MT-251

A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Single and Multiple Doses of MT-251 in Healthy Participants

19 - 55 years of age All Phase 1
A ASCEND-IBD Trial Center

A First-in-Human Single and Multiple Ascending Dose Study of MT-701

First-in-human study to evaluate the safety, tolerability, pharmacokinetics (PK), and immunogenicity of single and multiple doses of MT-701 in healthy participants.

19 - 55 years of age All Phase 1

Simplify language using AI